基本信息
职称 主任医师
职务 无
研究方向 胃肠道恶性肿瘤的内科治疗
电子邮件 rongbo_lin@163.com
个人简介
林榕波，男，硕士,副教授。本科与硕士毕业于福建医科大学。主要研究胃肠道恶性肿瘤的内科治疗和姑息支持治疗。现为福建省肿瘤医院肿瘤内科主任医师，中国抗癌协会肿瘤整体评估专业委员会副主任委员，福建省抗癌协会癌痛专委会主任委员，CSCO胃癌专家委员会委员，中国抗癌协会肿瘤靶向治疗专委会常委，中国抗癌协会癌症康复和姑息治疗专委会委员，中国抗癌协会中西医整合肿瘤专委会委员，中国医疗保健国际交流促进会肿瘤舒缓治疗学分会常委，中国康复医学会慢病康复专委会委员，福建省抗癌协会肿瘤心理专委会副主任委员，福建省中西医结合学会消化系统疾病学分会委员会副主任委员，福建省抗癌协会中西医整合肿瘤专委会常委，福建省抗癌协会肿瘤内科专业委员会委员，福建省肿瘤转化医学重点实验室成员，2012-2015年援博茨瓦纳公主玛丽娜医院。在国内外重要学术期刊和会议上发表论文50多篇。
主要科研项目
1、建立基于二代测序的新兴生物标记物用于患者自控氢吗啡酮在重度癌痛患者中的疗效预测研究，福建省科技厅社会发展科技引导性项目，2023.1-2025.12，主持
2、基于二代测序平台建立腹膜转移胃癌预测模型及基础应用研究，福建省科技厅自然科学基金面上项目，2019.4-2022.4，主持
3、阿帕替尼逆转胃癌多药耐药的研究，福建省卫健委科技计划项目医学创新课题，2016.10-2019.9，主持
4、卡瑞利珠单抗联合阿帕替尼加紫杉醇/奥沙利铂/亚叶酸钙/氟尿嘧啶（POF）一线治疗晚期胃癌II期临床研究，中国抗癌协会-恒瑞抗血管生成靶向肿瘤研究基金，2020.1-2023.12，主持
获奖经历
1、2022年，福建省抗癌学会科技奖三等奖（第一）
2、2018年，福建省抗癌学会科技奖三等奖（第四）
近五年发表的主要论文
1.Lin R, Zhu J, Luo Y, Lv X, Lu M, Chen H, Zou H, Zhang Z, Lin S, Wu M, Li X, Zhou M, Zhao S, Su L, Liu J, Huang C. Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial. J Natl Compr Canc Netw. 2022.
2.Lin R, Lin S, Feng S, Wu Q, Fu J, Wang F, Li H, Li X, Zhang G, Yao Y, Xin M, Lai T, Lv X, Chen Y, Yang S, Lin Y, Hong L, Cai Z, Wang J, Lin G, Lin S, Zhao S, Zhu J, Huang C. Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial. J Natl Compr Canc Netw. 2021.
3.Zhao S, Xu C,Lin R. Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study. Med Sci Monit. 2020.
4.Wang Q, Ye Y,Lin R, Weng S, Cai F, Zou M, Niu H, Ge L, Lin Y. Analysis of the expression, function, prognosis and co-expression genes of DDX20 in gastric cancer. Comput Struct Biotechnol J. 2020.
5.Song J, Yang J,Lin R, Cai X, Zheng L, Chen Y. Molecular heterogeneity of guanine nucleotide binding-protein γ subunit 4 in left- and right-sided colon cancer. Oncol Lett. 2020 Dec;20(6):334. doi: 10.3892/ol.2020.12197. Epub 2020 Oct 7. Erratum in: Oncol Lett. 2021.
6.Zhao S, Fan N, Li H, Liu J, Huang F, Chen Y, Zhou M, Yu J,Lin R. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. Ann Transl Med.
7.Deng Y, Chen X, Huang C, Chen G, Chen F, Lu J, Shi X, He C, Zeng Z, Qiu Y, Chen J,Lin R, Chen Y, Chen J. EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions. J Cancer. 2019.
8.He J, Liu Y, Liu C, Hu H, Sun L, Xu D, Li J, Wang J, Chen X,Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Fang M, Li E, Xu Y, Chen Y, Li J, Cui Y, Pan Z, Zhang S, Yuan Y, Ding K. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231152350.
9.Su L, Zhao S, Yin Y, Huang F, Zhu J, Chen L; FNF Independent Investigations Group;Lin R. POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. Front Med (Lausanne). 2022.
10.Zhao S, Su L, Chen Y, Li X, Lin P, Chen W, Fang W, Zhu J, Li H, Ren L, Liu J, Hong Y, Lin S, Fan N,Lin R. Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer. Front Oncol. 2022.
11.Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY,Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021.
12.Xu C, Si L, Wang W, Li Z, Song Z, Wang Q, Liu A, Yu J, Fang W, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Pu X,Lin R, Liu W, Rao C, Lv D, Yu Z, Lei L, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Hu X, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Ge R, Dai E, Han Y, Pan W, Luo J, Jia H, Dong X, Pang F, Wang K, Wang L, Zhu Y, Xie Y, Lin X, Cai J, Wei J, Lan F, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Wei Q, Kang J, Zhang J, Zhang C, Yu G, Ou J, Shi L, Li Z, Liu Z, Liu J, Yang N, Wu L, Wang H, Jin G, Yang L, Wang G, Fang M, Fang Y, Li Y, Wang X, Zhang Y, Ma S, Wang B, Zhang X, Song Y, Lu Y. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Thorac Cancer. 2022.
13.Liu J, Li H, Zhao S,Lin R, Yu J, Fan N. The Expression Pattern of Ferroptosis-Related Genes in Colon Adenocarcinoma: Highly Correlated to Tumor Microenvironment Characteristics. Front Genet. 2022.
14.Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, Qiu M,Lin R, Zhang H, Lan P, Wu X, Liu G, Wan Y, Liu M, Zhou Z, Huang Y, Li F, Zhang J, Cai Y, Ma T, Zhou J, Wang H, Ling J, Cai Y, Wu Z, Luo S, Ling L, Deng Y. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial. Oncologist. 2021.
15.陈军,聂铃,赵珅,林榕波,柯熹.步行运动联合静脉注射甲钴胺对胃肠肿瘤患者化疗所致周围神经毒性的改善效果[J].中国当代医药,2022.
16.林榕波,赵珅,苏丽玉.紫杉醇和奥沙利铂联合5-氟尿嘧啶和亚叶酸二线治疗晚期胆管癌38例疗效观察.福建医药杂志,2021.
17.赵珅,黄峰,林榕波.控制营养状态评分评估根治性胃癌切除术患者预后的临床价值.检验医学与临床,2020.
18.李惠,林榕波,林娇,刘捷,赵珅,范南峰.奥沙利铂脱敏治疗及皮试的探索性研究.现代肿瘤医学,2018.
19.刘捷,林榕波,范南峰.老年晚期胃癌替吉奥维持治疗疗效及预后分析.中华肿瘤防治杂志,2018.
